Search
Palladium Pd-103
go.drugbank.com/drugs/DB15016ExperimentalPalladium Pd-103 is under investigation in clinical trial NCT00247312 (Pd-103 Dose De-Escalation for Early Stage Prostate Cancer: A Prospective Randomized Trial).
Cilazapril
go.drugbank.com/drugs/DB01340ApprovedInvestigationalCilazapril is an ACE inhibtor class drug used in the treatment of hypertension and heart failure. It belongs to the angiotensin-converting enzyme inhibitors (ACE inhibitors) class of drugs.
Categories: P-glycoprotein inhibitorsQuaternium-15
go.drugbank.com/drugs/DB14198ApprovedIt is an anti-microbial agent by virtue of being a formaldehyde releaser, however this can also cause contact dermatitis, a symptom of an allergic reaction, especially in those with sensitive skin.
Norclozapine
go.drugbank.com/drugs/DB05766InvestigationalIt combines an atypical antipsychotic efficacy profile with the added potential benefit of enhanced cognition, thereby addressing one of the major challenges in treating schizophrenia today.
Trimethaphan
go.drugbank.com/drugs/DB01116ApprovedInvestigationalA nicotinic antagonist that has been used as a ganglionic blocker in hypertension, as an adjunct to anesthesia, and to induce hypotension during surgery.
Estramustine
go.drugbank.com/drugs/DB01196ApprovedWithdrawnA nitrogen mustard linked to estradiol, usually as phosphate; used to treat prostatic neoplasms; also has radiation protective properties.
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsAnidulafungin
go.drugbank.com/drugs/DB00362ApprovedAnidulafungin or Eraxis is an anti-fungal drug manufactured by Pfizer that gained approval by the Food and Drug Administration (FDA) in February 21, 2006; it was previously known as LY303366.
Levallorphan
go.drugbank.com/drugs/DB00504ApprovedAn opioid antagonist with properties similar to those of naloxone; in addition it also possesses some agonist properties.
Anethole trithione
go.drugbank.com/drugs/DB13853ApprovedAnethole trithione (ATT) appears to have a broad range of unique functions, from increasing salivary secretion to help treat xerostomia [A27165, A32618, A32620, A32621], to demonstrating an ability to … inhibit carcinogenesis by increasing the activity of electrophile detoxification enzymes [A32619], and even being used as an adjunctive therapy for cholecystitis, gallstone, indigestion, and acute/chronic
Setmelanotide
go.drugbank.com/drugs/DB11700ApprovedInvestigational[L24474] It is an agonist of the melanocortin 4 receptor. … [A224449] Patients taking setmelanotide experienced an average weight loss of 0.6 kg/week.